Core Viewpoint - AstraZeneca is significantly expanding its manufacturing capabilities in the U.S. with a $2 billion investment, which is part of a larger $50 billion global investment program aimed at enhancing its drug production and innovation [2][3]. Investment Details - The company is investing $2 billion to expand its drug-making capabilities in Maryland, specifically at an existing plant in Frederick and a new facility in Gaithersburg [2]. - The Gaithersburg plant is expected to double its current capacity, allowing the production of the entire rare disease portfolio [3]. - Both facilities will incorporate artificial intelligence (AI) and automation, with plans to be fully operational by 2029 [3]. Financial Position - AstraZeneca held over $6 billion in cash at the end of its most recently reported quarter, providing the resources necessary for such ambitious projects [6]. - The company's stock rose nearly 3% following the announcement, outperforming the S&P 500 index, which increased by almost 1% [1]. Market Context - The investment in Maryland is seen as a strategic move to onshore rare disease drugs, capitalizing on the size and resilience of the U.S. market [6]. - The company's market capitalization stands at $275 billion, with a gross margin of 73.25% and a dividend yield of 1.76% [5].

TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of executive management will present at three upcoming investor conferences in December as follows: 8th Annual Evercore Healthcare ConferenceWednesday, December 3, 2025, at 8:20 A.M. Eastern Time (ET)Piper Sandler 37th Annual Healthcare ConferenceWednesday, December 3, 2025, at 11:00 A.M. Eastern Time (ET)Citi’s 2025 G ...

TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of executive management will present at three upcoming investor conferences in December as follows: 8th Annual Evercore Healthcare ConferenceWednesday, December 3, 2025, at 8:20 A.M. Eastern Time (ET)Piper Sandler 37th Annual Healthcare ConferenceWednesday, December 3, 2025, at 11:00 A.M. Eastern Time (ET)Citi’s 2025 G ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

RAHWAY, N.J .--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEXâ,ç¢ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev® (enfortumab vedotin-eifv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who ar. ...

In my article from October, "My Top 5 Biotech Stocks Big Pharma Could Buy Next," I mentioned how Phathom Pharmaceutical's ( PHAT ) Voquezna and Voquezna Triple Pak is actively capturing share in the U.S. GERD and H. pylori infection treatment markets.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, ...

PALO ALTO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that, with respect to the voluntary distribution by Datavault AI Inc. (“Datavault AI”) (Nasdaq: DVLT) of Dream Bowl 2026 Meme Coins to record holders o ...

Nvidia Share Price Gains BigShares of Nvidia were up 1.4 per cent after Reuters reported, citing people familiar with the matter, that the Trump administration is considering greenlighting sales of Nvidia's H200 AI chips to China. New York Fed President John Williams, a voting member of the Federal Open Market Committee, said the central bank can still cut rates "in the near term" without putting its inflation goal at risk.Google-Owner Alphabet Stock GainsEli Lilly shares hit a record and were up 2 per cent ...

Core Insights - Eli Lilly has achieved a market capitalization exceeding one trillion dollars, becoming the first health industry company to reach this milestone [2][4] - The company's growth is primarily driven by the rising demand for weight loss drugs, particularly its offerings tirzepatide, Mounjaro, and Zepbound [5][8] Financial Performance - Eli Lilly's stock price has increased by 35% this year, significantly contributing to its market valuation [5] - In the third quarter, the company generated over $10 billion from its weight loss drugs, which accounted for more than half of its total sales of $17.6 billion during that period [7] - By October, the weight loss drugs had already generated $25 billion in revenue, surpassing the company's total revenue for the entire year of 2020 [8] Competitive Landscape - Eli Lilly is in a competitive race with Novo Nordisk, which is also seeking FDA approval for its oral weight loss drug [9] - Both companies are reducing prices for their injectable weight loss drugs in response to calls from the Trump administration [9][10] - Despite Eli Lilly's success, Novo Nordisk has faced a decline in investor confidence, with its stock value dropping sharply in 2025 [11] Innovation and Future Prospects - Eli Lilly is developing a new oral weight loss drug, orforglipron, which is a candidate for early FDA approval [8] - The company emphasizes a shift in focus from merely delivering medicine to providing personalized and accessible healthcare solutions [13]